On March 30th, Zhaoyan New Drug rose 6.15%, and the China-Europe Medical Innovation Stock A Fund held a heavy position in this stock.

Securities Star News: On March 30, Zhaoyan New Medicine (603127) rose 6.15%, closing at 32.1 yuan. The turnover rate was 7.35%, with trading volume of 463.2 thousand lots and trading value of 1.467 billion yuan. This stock is a popular concept stock in areas including gene editing, CAR-T therapy, pharmaceuticals, innovative drugs, Healthy China, stem cells, and AI-enabled healthcare. Regarding the March 30 capital flow data, main force net inflow was 78.227 million yuan, accounting for 5.33% of the total trading value; retail investors’ net inflow was 77.0376 million yuan, accounting for 5.25% of the total trading value; and individual investors’ net outflow was 155 million yuan, accounting for 10.58% of the total trading value. In terms of margin financing and securities lending, over the past 5 days margin financing saw a net outflow of 5.3982 million, with the margin financing balance decreasing; while securities lending saw a net inflow of 46.0 million, with the securities lending balance increasing.

For the top ten public funds holding a heavy position in Zhaoyan New Medicine, please see the table below:

Within the past 90 days, a total of 3 institutions have issued ratings for this stock, with 2 buy ratings. Over the past 90 days, the institutions’ average target price was 39.0.

According to the 2025 fund annual report data on publicly offered funds’ heavy holdings, there are 45 public funds holding a heavy position in this stock. Among them, the public fund with the largest holding is the China Europe Fund’s China Europe Medical Innovation Stock A. China Europe Medical Innovation Stock A currently has a scale of 4.18 billion yuan, with the latest net value of 1.4332 (as of March 27), up 5.51% from the previous trading day, and up 14.2% over the past year. The current fund manager of this publicly offered fund is Ge Lan. The fund products managed by Ge Lan include: China Europe Medical and Health Mixed A, with a management period from September 29, 2016 to now, with a return rate of 92.52%; China Europe Mingrui New Starting Point Mixed, with a management period from July 12, 2018 to now, with a return rate of 80.47%;

The top ten heavy-holding stocks of China Europe Medical Innovation Stock A are as follows:

The above content has been compiled by Securities Star from publicly available information and generated by an AI algorithm (registration number: Wang Xin Suan Bei 310104345710301240019). It does not constitute investment advice.